Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Rα signaling

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9963-9970

  Brown, Valerie I ^a,b   Hulitt, Jessica ^a   Fish, Jonathan ^a   Sheen, Cecilia ^a   Bruno, Marlo ^a   Xu, Qing ^b   Carroll, Martin ^b   Fang, Junjie ^a   Teachey, David ^a   Grupp, Stephan A ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHATIC LEUKEMIA; LYMPHOPOIESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARRIER PROTEINS; CELL GROWTH PROCESSES; CYTOKINES; DRUG INTERACTIONS; HUMANS; INTERLEUKIN-7; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; JANUS KINASE 1; JANUS KINASE 3; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECOMBINANT PROTEINS; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; SIROLIMUS; STAT5 TRANSCRIPTION FACTOR;

EID: 35448953345     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4704     Document Type: Article

References (49)

1. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975;28:727-32.
2. Ettenger RB, Grimm EM. Target of rapamycin (TOR) inhibition in renal transplantation: clinical uses in various populations. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001;38:S22-8.
3. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004;10:6382-7S.
4. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
5. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
6. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46.
7. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
8. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004;100:657-66.
9. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect which is modulated by IL-7 mediated signaling. Proc Natl Acad Sci U S A 2003;100:15113-8.
10. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human all. Blood 2006;107:1149-55.
11. Miller JP, Izon D, DeMuth W, et al. The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med 2002;196:705-11.
12. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001;1:200-8.
13. Sims JE, Williams DE, Morrissey PJ, et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med 2000;192:671-80.
14. Hofmeister R, Khaled AR, Benbernou N, et al. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999;10:41-60.
15. Wei C, Zeff R, Goldschneider I. Murine pro-B cells require IL-7 and its receptor complex to up-regulate IL-7R α, terminal deoxynucleotidyltransferase, and c mu expression. J Immunol 2000;164:1961-70.
16. Corcoran AE, Smart FM, Cowling RJ, et al. The interleukin-7 receptor γ chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J 1996;15:1924-32.
17. Pribyl JA, LeBien TW. Interleukin 7 independent development of human B cells. Proc Natl Acad Sci U S A 1996;93:10348-53.
18. Dittel BN, LeBien TW. The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing cd34. J Immunol 1995;155:58-67.
19. Friend SL, Hosier S, Nelson A, et al. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol 1994;22:321-8.
20. Ray RJ, Furlonger C, Williams DE, Paige CJ. Characterization of thymic stromal-derived lymphopoietin (TSLP) in murine B cell development in vitro. Eur J Immunol 1996;26:10-6.
21. Levin SD, Koelling RM, Friend SL, et al. Thymic stromal lymphopoietin: A cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. J Immunol 1999;162:677-83.
22. Vosshenrich CA, Cumano A, Muller W, Di Santo JP, Vieira P. Thymic stromal-derived lymphopoietin distinguishes fetal from adult B cell development. Nat Immunol 2003;4:773-9.
23. Quentmeier H, Drexler HG, Fleckenstein D, et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia 2001;15:1286-92.
24. Kang J, Der SD. Cytokine functions in the formative stages of a lymphocyte's life. Curr Opin Immunol 2004;16:180-90.
25. Pandey A, Ozaki K, Baumann H, et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol 2000;1:59-64.
26. Park LS, Martin U, Garka K, et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med 2000;192:659-70.
27. Smart FM, Venkitaraman AR. Inhibition of interleukin 7 receptor signaling by antigen receptor assembly. J Exp Med 2000;191:737-42.
28. Sudo T, Nishikawa S, Ohno N, et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci U S A 1993;90:9125-9.
29. Sato AK, Yanai N, Okubo T, Mori KJ, Obinata M. Stromal cells provide signals different from cytokines for stat5 activation in hematopoietic cells. Cell Struct Function 2001;26:95-101.
30. Nosaka T, Kawashima T, Misawa K, et al. Stat5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999;18:4754-65.
31. Isaksen DE, Baumann H, Zhou B, et al. Uncoupling of proliferation and stat5 activation in thymic stromal lymphopoietin-mediated signal transduction. J Immunol 2002;168:3288-94.
32. Shah N, Oseth L, Tran H, Hirsch B, LeBien TW. Clonal variation in the B-lineage acute lymphoblastic leukemia response to multiple cytokines and bone marrow stromal cells. Cancer Res 2001;61:5268-74.
33. Benjamin D, Sharma V, Knobloch TJ, et al. B cell IL-7: Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol 1994;152:4749-57.
34. Touw I, Pouwels K, van Agthoven T, et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990;75:2097-101.
35. Scupoli MT, Vinante F, Krampera M, et al. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 2003;88:1229-37.
36. Wasserman R, Zeng XX, Hardy RR. The evolution of B precursor leukemia in the Emu-ret mouse. Blood 1998;92:273-82.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
38. Kim JM, Fang J, Rheingold S, et al. Cytoplasmic m heavy chain confers sensitivity to dexamethasone-induced apoptosis in early B-lineage acute lymphoblastic leukemia. Cancer Res 2002;62:4212-6.
39. Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 2004;22:1111-20.
40. Barker J, Verfaillie CM. A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes. Leukemia 2000;14:1614-20.
41. Lin JX, Migone TS, Tsang M, et al. The role of shared receptor motifs and common STAT proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331-9.
42. Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol 2005;175:7325-31.
43. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-54.
44. Dorshkind K. Understanding how pre-B cells come of age. Nat Immunol 2000;1:369-70.
45. Carvalho TL, Mota-Santos T, Cumano A, Demengeot J, Vieira P. Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin 7(-/-) mice. J Exp Med 2001;194:1141-50.
46. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994;180:1955-60.
47. Carpino N, Thierfelder WE, Chang MS, et al. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development. Mol Cell Biol 2004;24:2584-92.
48. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993;177:305-16.
49. Abraham N, Ma MC, Snow JW, et al. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene 2005;24:5252-7.